参考文献/References:
[1] Hwang AY,Dietrich E,Pepine CJ,et al. Resistant hypertension:mechanisms and treatment[J]. Curr Hypertens Rep,2017,19(7):56.
[2] Noubiap JJ,Nansseu JR,Nyaga UF,et al. Global prevalence of resistant hypertension:a meta-analysis of data from 3.2 million patients[J]. Heart,2019,105(2):98-105.
[3] Tan K,Lai Y,Chen W,et al. Selective renal denervation guided by renal nerve stimulation:mapping renal nerves for unmet clinical needs[J]. J Hum Hypertens,2019,33(10):716-724.
[4] Linz D,Hohl M,Elliott AD,et al. Modulation of renal sympathetic innervation:recent insights beyond blood pressure control[J]. Clin Auton Res,2018,28(4):375-384.
[5] Krum H,Schlaich M,Whitbourn R,et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study[J]. Lancet, 2009,373(9671):1275-1281.
[6] Esler MD,Krum H,Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial[J]. Lancet,2010,376(9756): 1903-1909.
[7] Bhatt DL,Kandzari DE,O’neill WW,et al. A controlled trial of renal denervation for resistant hypertension[J]. N Engl J Med,2014,370(15):1393-1401.
[8] Kandzari DE,Bhatt DL,Brar S,et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial[J]. Eur Heart J,2015,36(4):219-227.
[9] Townsend RR,Mahfoud F,Kandzari DE,et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED):a randomised,sham-controlled,proof-of-concept trial[J]. Lancet,2017,390(10108):2160-2170.
[10] Kandzari DE,B?hm M,Mahfoud F,et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs:6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial[J]. Lancet,2018,391(10137):2346-2355.
[11] Azizi M,Schmieder RE,Mahfoud F,et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO):a multicentre,international,single-blind,randomised,sham-controlled trial[J]. Lancet,2018,391(10137):2335-2345.
[12] B?hm M,Kario K,Kandzari DE,et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal):a multicentre,randomised,sham-controlled trial[J]. Lancet,2020,395(10234):1444-1451.
[13] de Maria GL. Will the SPYRAL-OFF MED pivotal trial switch our interest in renal denervation back on?[J]. Cardiovasc Res,2020,116(11):e140-e142.
[14] 勾白冰,黄晶. 射频与超声能源在肾交感神经消融的对比研究[J]. 心血管病学进展,2019,40(1):20-23.
[15] Mabin T,Sapoval M,Cabane V,et al. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension[J]. EuroIntervention,2012,8(1):57-61.
[16] Stiermaier T,Okon T,Fengler K,et al. Endovascular ultrasound for renal sympathetic denervation in patients with therapy-resistant hypertension not responding to radiofrequency renal sympathetic denervation[J]. EuroIntervention,2016,12(2):e282-e289.
[17] Fengler K,Rommel KP,Blazek S,et al. A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension (RADIOSOUND-HTN)[J]. Circulation,2019,139(5):590-600.
[18] Azizi M,Schmieder RE,Mahfoud F,et al. Six-month results of treatment-blinded medication titration for hypertension control following randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO trial[J]. Circulation,2019 Mar 17. DOI:10.1161/CIRCULATIONAHA.119.040451.
[19] Mauri L,Kario K,Basile J,et al. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation:The RADIANCE-HTN and REQUIRE clinical study designs[J]. Am Heart J,2018,195:115-129.
[20] Daemen J,Mahfoud F,Kuck KH,et al. Safety and efficacy of endovascular ultrasound renal denervation in resistant hypertension:12-month results from the ACHIEVE study[J]. J Hypertens,2019,37(9):1906-1912.
[21] Chernin G,Szwarcfiter I,Bausback Y,et al. Renal sympathetic denervation system via intraluminal ultrasonic ablation:therapeutic intravascular ultrasound design and preclinical evaluation[J]. J Vasc Interv Radiol,2017,28(5):740-748.
[22] Chernin G,Szwarcfiter I,Scheinert D,et al. First-in-man experience with a novel catheter-based renal denervation system of ultrasonic ablation in patients with resistant hypertension[J]. J Vasc Interv Radiol,2018,29(8):1158-1166.
[23] Schmieder RE,Ott C,Bramlage P. Non-invasive renal denervation:update on external ultrasound approaches[J]. Curr Hypertens Rep,2016,18(6):48.
[24] Neuzil P,Ormiston J,Brinton T J,et al. Externally delivered focused ultrasound?for renal denervation[J]. JACC Cardiovasc Interv,2016,9(12):1292-1299.
[25] Schmieder RE,Ott C,Toennes SW,et al. PhaseⅡrandomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE Ⅳ[J]. J Hypertens,2018,36(3):680-689.
[26] Wang Q,Guo R,Rong S,et al. Noninvasive renal sympathetic denervation by extracorporeal high-intensity focused ultrasound in a pre-clinical canine model[J]. J Am Coll Cardiol,2013,61(21):2185-2192.
[27] 陈姝蓓,高大中,容顺康,等. 高强度聚焦超声体外消融犬肾交感神经[J]. 中国医学影像技术,2013,29(6):867-870.
[28] Rong S,Zhu H,Liu D,et al. Noninvasive renal denervation for resistant hypertension using high-intensity focused ultrasound[J]. Hypertension,2015,66(4):e22-e25.
[29] de Jong MR,Hoogerwaard AF,Adiyaman A,et al. Renal nerve stimulation identifies aorticorenal innervation and prevents inadvertent ablation of vagal nerves during renal denervation[J]. Blood Press,2018,27(5):271-279.
[30] Tsioufis C,Dimitriadis K,Tsioufis P,et al. ConfidenHT? System for diagnostic mapping of renal nerves[J]. Curr Hypertens Rep,2018,20(6):49.
[31] 郑小宇. 无创双频聚焦超声介导肾去交感化的实验研究[D]. 重庆: 重庆医科大学,2019.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(6):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(6):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(6):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(6):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(6):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(6):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(6):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]